3647 results for «604»
3647 results
TAVI and aortic valve procedures
11 Oct 2025 – From AICT-AsiaPCR 2025
Focusing on transcatheter aortic valve interventions, this session covers a broad spectrum of complex cases including emergent TAV-in-SAV procedures, management of severely calcified bicuspid valves, zero-contrast TAVI techniques, and strategies for hostile anatomies. It provides valuable insights into procedural planning and follow-up to optimize patient care...
Valve-in-valve in degenerated surgical bioprothesis mitral valve - LIVE Case
10 Oct 2025 – From AICT-AsiaPCR 2025
A 78-year-old male with a history of rheumatic disease underwent surgical mitral valve replacement (Perimount Magna 25), surgical aortic valve replacement (Perimount Magna), and CABG (LIMA–LAD) in 2010. He presented with symptomatic severe mitral regurgitation and normal LV function.
He was treated with implantation of a 26...
IVUS or OCT? Choosing the right imaging for the right lesion - A case-based debate
10 Oct 2025 – From AICT-AsiaPCR 2025
This case-based debate examines the complementary roles of IVUS and OCT imaging modalities in precision PCI. It highlights lesion-specific factors guiding modality choice, including left main disease, bifurcations, calcified plaques, and acute coronary syndromes, supported by real-world clinical cases demonstrating imaging-based decision-making.
EuroPCR 2018 Opening Ceremony and Ethica Awards
22 May 2018 – From EuroPCR 2018
Join J. Fajadet and W. Wijns for the EuroPCR 2018 Opening Ceremony and find out who this year's Ethica Awards winners are!
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
